AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32296873
Drug: Ivosidenib 500-mg
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivosidenib 500-mg QD
Trial: 32297945
Drug: Treatment Expectation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Expectation
Trial: 32298288
Drug: Combined neoadjuvant
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined neoadjuvant chemotherapy with bevacizumab
Trial: 32298699
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone treatment
Trial: 32298699
Drug: Oral microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral microbiota
Trial: 32298699
Drug: Sputum and
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum and oral microbiota
Trial: 32298906
Drug: High RT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High RT dose to the left hippocampus
Trial: 32298906
Drug: RT dose
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RT dose to the left hippocampus, left temporal lobe, left frontal lobe, and total frontal lobe
Trial: 32298906
Drug: RT dose
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RT dose to the thalamus and the left frontal lobe
Trial: 32298906
Drug: RT dose
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RT dose to the brain and thalamus
Trial: 32299118
Drug: Usual primary
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual primary care treatment in Dachau
Trial: 32299817
Drug: CIVO microinjected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIVO microinjected drugs
Trial: 32300671
Drug: Intranasal Ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Ketamine
Trial: 32300966
Drug: Propofol induction
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol induction dose
Trial: 32300966
Drug: Higher propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher propofol doses
Trial: 32300966
Drug: Excess propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Excess propofol dose
Trial: 32301062
Drug: 0.2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml/kg dose of IGIM
Trial: 32301063
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg/day
Trial: 32301063
Drug: Other hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Other hormonal medications
Trial: 32301063
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg/day and other hormonal medications
Trial: 32303379
Drug: QoR-15F scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QoR-15F scale administered pre-operation and on Postoperative day 1
Trial: 32303514
Drug: Inappropriate reasons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate reasons for ED presentation (no urgent treatment required)
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) as first-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) as second-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) as at least third-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in PsA as first-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in PsA as second-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in PsA as at least third-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in AS as first-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in AS as second-line biologic agent
Trial: 32303994
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) in AS as at least third-line biologic agent
Trial: 32304877
Drug: Biologics (n=557);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics (n=557); 51% anti-immunoglobulin E, 48% anti-IL-5/IL-5Rα; 76% of initiations from May 2018 were anti-IL-5/IL-5Rα
Trial: 32304877
Drug: Maintenance systemic
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance systemic corticosteroids (mSCS); median prednisone-equivalent daily dose of 10 mg
Trial: 32304877
Drug: Patients of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of hospital clinics, sites with fewer nonphysician staff, and with a recorded concurrent chronic obstructive pulmonary disease diagnosis
Trial: 32306096
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept 2 mg/0.05 mL monthly for three injections followed by every 8 weeks
Trial: 32307193
Drug: Substituting 50
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substituting 50 g/d egg for dairy products
Trial: 32307193
Drug: Substituting 50
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substituting 50 g/d egg for nuts/legumes
Trial: 32307193
Drug: Substituting 50
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substituting 50 g/d egg for red meat
Trial: 32307279
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose inactivated hepatitis-A virus (HAV) vaccine
Trial: 32307279
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose live attenuated varicella zoster virus (VZV) vaccine
Trial: 32307279
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose VZV vaccine
Trial: 32308505
Drug: FTD/TPI (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTD/TPI (35 mg/m²)
Trial: 32309426
Drug: NAC+CHO (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC+CHO (300 mL of oral carbohydrate administered 2 hours before surgery)
Trial: 32309426
Drug: NAC (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC (two cycles of chemotherapy followed by surgery)
Trial: 32310146
Drug: AGE-ON tablet
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGE-ON tablet training program
Trial: 32310699
Drug: Morphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine treatment with metoclopramide coadministration
Trial: 32310699
Drug: Morphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine treatment without metoclopramide
Trial: 32310699
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no morphine treatment)
Trial: 32312893
Drug: Sunitinib (multi-kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (multi-kinase inhibitor)
Trial: 32312891
Drug: Capivasertib monotherapy
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib monotherapy
Trial: 32312891
Drug: Capivasertib in
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib in combination with Fulvestrant
Trial: 32313451
Drug: Latiglutenase (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latiglutenase (900 mg)
Trial: 32313731
Drug: Heat shock
RxNorm normalized name: Human heat shock protein antigen 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat shock protein peptide complex-96 (HSPPC-96) vaccine
Trial: 32314268
Drug: Copanlisib (0.2-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (0.2-0.8 mg/kg intravenously) intermittently or weekly; Refametinib (30-50 mg twice daily orally) continuously or 4 days on/3 days off.
Trial: 32315434
Drug: Laser interstitial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser interstitial thermal therapy (LITT) using Robotic NeuroBlate System
Trial: 32316080
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (28-mg, 56-mg, or 84-mg) plus new oral antidepressant (OAD) administered twice a week for 4 weeks, followed by weekly or every-other-week for responders during a 48-week optimization/maintenance phase.
Trial: 32316080
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray plus new OAD
Trial: 32316977
Drug: Robot-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted therapy with customized forces
Trial: 32317004
Drug: Vitamin C,
RxNorm normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C, Thiamine and Steroids
Trial: 32318062
Drug: CCR4 targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCR4 targeting intervention, details on dosage and duration not available
Trial: 32318268
Drug: High-dose meropenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose meropenem (2-g infusion over 3 h every 8 h)
Trial: 32318268
Drug: Standard-dose meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose meropenem (1-g infusion over 3 h every 8 h)
Trial: 32318268
Drug: Standard-dose meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose meropenem
Trial: 32318271
Drug: ThrIVe-B programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThrIVe-B programme (psychological therapy)
Trial: 32318621
Drug: Blarcamesine (ANAVEX2-73),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blarcamesine (ANAVEX2-73), a selective sigma-1 receptor agonist, administered over a 57-week Phase 2a trial.
Trial: 32319040
Drug: Posaconazole 300
RxNorm normalized name: posaconazole 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 300 mg twice daily on day 1 and then once daily for up to 28 days
Trial: 32319040
Drug: Posaconazole 300
RxNorm normalized name: posaconazole 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 300 mg tablet
Trial: 32319144
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements (DSs), average 9.12 (SD = 6.46) prescription drugs daily, 25 of 40 participants (62.5%) reported taking ≥1 DS daily.
Trial: 32319144
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (part of clinical trial), specific dosage and duration not mentioned.
Trial: 32321635
Drug: Old and
RxNorm normalized name: Cold and Hot
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old and new antirheumatic drugs
Trial: 32323313
Drug: Functional competence
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional competence on PASS (Cognitively Mediated Instrumental Activities of Daily Living)
Trial: 32324927
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks)
Trial: 32324981
Drug: Revefenacin 175
RxNorm normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 175 µg + Formoterol 20 µg
Trial: 32324981
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Formoterol 20 µg
Trial: 32324981
Drug: Revefenacin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin + Formoterol (combined administration)
Trial: 32324981
Drug: Formoterol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol alone (evening administration)
Trial: 32325037
Drug: MVA-MERS-S vaccine
RxNorm normalized name: MVA-SARS-2-S
DrugBank: MVA-SARS-2-S (DB16432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-MERS-S vaccine
Trial: 32325043
Drug: Parenteral anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral anticoagulation only
Trial: 32325171
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (200 mg/m2) for conditioning prior to ASCT
Trial: 32325220
Drug: SC-003 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC-003 antibody Fab fragment
Trial: 32325461
Drug: Post-Transplantation Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-Transplantation Cyclophosphamide (PTCy) and Ruxolitinib (45 mg from day-7 to day-2, 15 mg from day+5 to day+100)
Trial: 32325480
Drug: GSK3050002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3050002 at 30 mg/kg/week
Trial: 32325480
Drug: GSK3050002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3050002 at 300 mg/kg/week
Trial: 32327102
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (n=7)
Trial: 32327102
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (n=29)
Trial: 32327472
Drug: TAK-659, 60-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-659, 60-120 mg, once-daily oral administration in 28-day cycles until disease progression or unacceptable toxicity
Trial: 32328115
Drug: Omalizumab 8
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab 8 mg/kg per month (n=36)
Trial: 32328115
Drug: Omalizumab 16
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab 16 mg/kg per month (n=36)
Trial: 32328660
Drug: Tepotinib 215,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib 215, 300 or 500 mg once daily
Trial: 38575731
Drug: Tepotinib 500
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tepotinib 500 mg once daily
Trial: 39037964
Drug: Ibrutinib treatment
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib treatment
Trial: 32329093
Drug: Fractional CO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO treatment
Trial: 32329527
Drug: Lacosamide as
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lacosamide as add-on therapy
Trial: 32330099
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy and intraventricular methotrexate
Trial: 32330102
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of peg-filgrastim during dose-dense paclitaxel regimen
Trial: 32330242
Drug: Pexidartinib (PLX3397)
RxNorm normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib (PLX3397) at doses of 800 to 5000 mg per day
Trial: 32330242
Drug: Pexidartinib (PLX3397)
RxNorm normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib (PLX3397) at doses of ≥2000 mg
Trial: 32330242
Drug: Pexidartinib (PLX3397)
RxNorm normalized name: pexidartinib
DrugBank: Pexidartinib (DB12978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pexidartinib (PLX3397) in dose expansion
Trial: 32330244
Drug: Eltrombopag (EPAG)
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag (EPAG) administered at doses escalating from 50 to 300 mg/d.
Trial: 32330510
Drug: Gliclazide modified
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide modified release (MR), taken once daily for 14-18 weeks.
Trial: 32331767
Drug: BRCA positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRCA positive women after chemotherapy treatment
Trial: 32331767
Drug: BRCA negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRCA negative women after chemotherapy treatment
Trial: 32331767
Drug: Untested/low risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untested/low risk controls after chemotherapy treatment
Trial: 32331767
Drug: Before chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before chemotherapy treatment AMH levels in BRCA positive and negative women
Trial: 32331936
Drug: Alirocumab 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 40 mg (<50 kg) or 75 mg (≥50 kg) every 2 weeks (Q2W)
Trial: 32331936
Drug: Alirocumab 150
RxNorm normalized name: alirocumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 150 mg (<50 kg) or 300 mg (≥50 kg) every 4 weeks (Q4W)
Trial: 32333591
Drug: Donepezil (Cholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (Cholinesterase Inhibitor) started at 5 mg daily, increased to 10 mg daily if tolerated, maintained for 52 weeks.
Trial: 32333591
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in UPSIT score from 0 to 8 weeks with Donepezil treatment.
Trial: 32333853
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for 18 months after initial 6 months treatment
Trial: 32333853
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 18 months after initial 6 months treatment
Trial: 32334566
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum HDL < 1.03 mmol/L
Trial: 32334566
Drug: Preoperative serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative serum HDL > 1.03 mmol/L
Trial: 32335374
Drug: Vorolanib 200
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 200 mg plus everolimus 5 mg once daily
Trial: 32335374
Drug: Vorolanib 100
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 100 mg plus everolimus 5 mg once daily
Trial: 32335374
Drug: Vorolanib 150
RxNorm normalized name: Vorolanib
DrugBank: Vorolanib (DB15247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorolanib 150 mg plus everolimus 5 mg once daily
Trial: 32336987
Drug: EMOTION intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMOTION intervention (transdiagnostic indicated preventive cognitive behavioral therapy)
Trial: 32337054
Drug: anti-TNFα therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-TNFα therapy
Trial: 32337059
Drug: 1.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/day of phosphatidylcholine (PPC) as adjunctive treatment to standard care
Trial: 32337094
Drug: Erlotinib, cetuximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib, cetuximab, and bevacizumab (triplet combination)
Trial: 32337475
Drug: 22 g
RxNorm normalized name: Empty Carpuject 2 mL 22 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 g freeze-dried blueberries for 8 weeks
Trial: 32337496
Drug: Talazoparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (1 mg)
Trial: 32337496
Drug: Physician's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's Choice of Chemotherapy (PCT)
Trial: 32338433
Drug: rAHF 2
RxNorm normalized name: rAHF
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAHF 2 mL prophylaxis